# IO Biotech Inc. (IOBT)

Source: https://www.quantisnow.com/company/IOBT
Generated: 2026-11-08T04:42:25.620Z

- Ticker: IOBT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: iobiotech.com

## About

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.

## Latest IOBT news and filings

- 2026-04-06 20:05 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by IO Biotech Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-io-biotech-inc-6489258)
- 2026-03-31 12:00 UTC [SEC Form 8-K] [IO Biotech Inc. filed SEC Form 8-K: Bankruptcy or Receivership](https://www.quantisnow.com/insight/io-biotech-inc-filed-sec-form-8-k-bankruptcy-or-receivership-6478014)
- 2026-02-13 22:22 UTC [SEC Form 8-K] [SEC Form 8-K filed by IO Biotech Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-io-biotech-inc-6393234)
- 2026-02-06 21:10 UTC [SEC Form SCHEDULE 13G filed by IO Biotech Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-io-biotech-inc-6379767)
- 2026-01-30 21:53 UTC [SEC Form 8-K] [SEC Form 8-K filed by IO Biotech Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-io-biotech-inc-6368294)
- 2026-01-30 13:05 UTC [IO Biotech Provides Corporate Update](https://www.quantisnow.com/insight/io-biotech-provides-corporate-update-6367135)
- 2026-01-26 15:01 UTC [Analyst Downgrade] [IO Biotech downgraded by Piper Sandler with a new price target](https://www.quantisnow.com/insight/io-biotech-downgraded-by-piper-sandler-with-a-new-price-6360326)
- 2026-01-24 00:05 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by IO Biotech Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-io-biotech-inc-6359774)
- 2026-01-21 11:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by IO Biotech Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-io-biotech-inc-6355094)
- 2026-01-21 10:30 UTC [IO Biotech Announces Exploration of Strategic Alternatives](https://www.quantisnow.com/insight/io-biotech-announces-exploration-of-strategic-alternatives-6355030)
- 2026-01-08 13:40 UTC [Analyst Downgrade] [IO Biotech downgraded by Morgan Stanley with a new price target](https://www.quantisnow.com/insight/io-biotech-downgraded-by-morgan-stanley-with-a-new-price-6342418)
- 2025-12-19 22:18 UTC [SEC Form 8-K] [SEC Form 8-K filed by IO Biotech Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-io-biotech-inc-6324258)
- 2025-12-15 21:05 UTC [IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications](https://www.quantisnow.com/insight/io-biotech-announces-publication-of-five-year-clinical-outcomes-of-phase-6315929)
- 2025-11-26 15:46 UTC [IO Biotech Announces Participation in Upcoming December Investor Conferences](https://www.quantisnow.com/insight/io-biotech-announces-participation-in-upcoming-december-investor-conferences-6294729)
- 2025-11-21 21:44 UTC [SEC Form 8-K] [SEC Form 8-K filed by IO Biotech Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-io-biotech-inc-6290505)
- 2025-11-20 13:30 UTC [Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For](https://www.quantisnow.com/insight/remeasuring-biotech-pipelines-the-valuation-signal-investors-have-been-waiting-6288205)
- 2025-11-18 11:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by IO Biotech Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-io-biotech-inc-6283850)
- 2025-11-14 23:39 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by IO Biotech Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-io-biotech-inc-6281609)
- 2025-11-14 14:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by IO Biotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-io-biotech-inc-6279320)
- 2025-11-14 13:10 UTC [SEC Form 8-K] [IO Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/io-biotech-inc-filed-sec-form-8-k-results-of-operations-6279119)
- 2025-11-14 13:05 UTC [IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights](https://www.quantisnow.com/insight/io-biotech-reports-third-quarter-2025-financial-results-and-provides-6279107)
- 2025-11-12 13:30 UTC [IO Biotech Announces Participation in Upcoming Investor Conferences](https://www.quantisnow.com/insight/io-biotech-announces-participation-in-upcoming-investor-conferences-6273101)
- 2025-11-07 14:00 UTC [IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)](https://www.quantisnow.com/insight/io-biotech-presents-pre-clinical-data-highlighting-the-potential-of-additional-6267536)
- 2025-10-27 12:30 UTC [Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology](https://www.quantisnow.com/insight/nanomedicine-breakthrough-technology-redefining-drug-delivery-bioavailability-in-oncology-6245514)
- 2025-10-20 06:30 UTC [IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025](https://www.quantisnow.com/insight/io-biotech-presents-phase-3-results-for-cylembio-plus-keytruda-6237860)
- 2025-09-30 12:32 UTC [Analyst Downgrade] [IO Biotech downgraded by TD Cowen](https://www.quantisnow.com/insight/io-biotech-downgraded-by-td-cowen-6215450)
- 2025-09-30 12:32 UTC [Analyst Downgrade] [IO Biotech downgraded by Morgan Stanley with a new price target](https://www.quantisnow.com/insight/io-biotech-downgraded-by-morgan-stanley-with-a-new-price-6215449)
- 2025-09-29 11:17 UTC [SEC Form 8-K] [IO Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/io-biotech-inc-filed-sec-form-8-k-regulation-fd-disclosure-6213748)
- 2025-09-29 11:05 UTC [IO Biotech Provides Update Following Pre-BLA Meeting with FDA](https://www.quantisnow.com/insight/io-biotech-provides-update-following-pre-bla-meeting-with-fda-6213730)
- 2025-09-23 12:05 UTC [IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025](https://www.quantisnow.com/insight/io-biotech-announces-late-breaking-abstract-in-advanced-melanoma-selected-for-6208900)
- 2025-09-15 12:30 UTC [Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth](https://www.quantisnow.com/insight/innovative-therapeutics-pipeline-positions-industry-for-strong-market-growth-6200456)
- 2025-09-04 12:05 UTC [IO Biotech Announces Participation in Upcoming Investor Conferences](https://www.quantisnow.com/insight/io-biotech-announces-participation-in-upcoming-investor-conferences-6189362)
- 2025-08-19 21:09 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by IO Biotech Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-io-biotech-inc-6172175)
- 2025-08-14 20:45 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by IO Biotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-io-biotech-inc-6166760)
- 2025-08-14 20:31 UTC [SEC Form 8-K] [IO Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/io-biotech-inc-filed-sec-form-8-k-results-of-operations-6166614)
- 2025-08-14 20:05 UTC [IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights](https://www.quantisnow.com/insight/io-biotech-reports-second-quarter-2025-financial-results-and-provides-6165837)
- 2025-08-14 16:30 UTC [Biotech Stocks Rally as Oncology Market Targets $866B by 2034](https://www.quantisnow.com/insight/biotech-stocks-rally-as-oncology-market-targets-866b-by-2034-6165329)
- 2025-08-11 12:00 UTC [SEC Form 8-K] [IO Biotech Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/io-biotech-inc-filed-sec-form-8-k-other-events-6157554)
- 2025-08-11 12:00 UTC [Earnings Date] [IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed](https://www.quantisnow.com/insight/io-biotech-announces-clinical-improvement-in-progression-free-survival-demonstrated-6157495)
- 2025-08-10 12:00 UTC [Earnings Date] [IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma](https://www.quantisnow.com/insight/io-biotech-to-announce-topline-results-of-pivotal-phase-3-6157090)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IOBT
- Earnings history: https://www.quantisnow.com/earnings/IOBT
- Dividend history: https://www.quantisnow.com/dividends/IOBT
- Insider transactions: https://www.quantisnow.com/insiders/IOBT
- Options chain: https://www.quantisnow.com/options/IOBT
- SEC 8-K filings only: https://www.quantisnow.com/company/IOBT/8-k
- RSS and alerts for IOBT: https://www.quantisnow.com/docs/rss-feeds.md